Li Yaotan, Hou Jinyi, Zhang Xinghua, Wu Xiaochang, Lin Shijia, Liu Weijing, Wang Yaoxian, Zheng Huijuan
Dongzhimen Hospital, Affiliated to Beijing University of Chinese Medicine, Beijing, China.
Institute of Nephrology, Beijing University of Chinese Medicine, Beijing, China.
Ren Fail. 2025 Dec;47(1):2521457. doi: 10.1080/0886022X.2025.2521457. Epub 2025 Jun 23.
Single-cell RNA sequencing (scRNA-seq) has revolutionized kidney disease research by enabling high-resolution transcriptomic analysis at the cellular level. This technology can overcome the limitations of traditional bulk-sequencing; reveal disease-progression trajectories, intercellular communication networks, and cellular heterogeneity; and provide crucial insights into disease mechanisms, thereby facilitating the development of targeted therapies and personalized treatment strategies. We conducted a bibliometric analysis of publications describing the use of scRNA-seq in kidney disease research from 2015 to 2024 using the Web of Science Core Collection (WoSCC) database. Data analysis was performed using the R packages Bibliometrix, VOSviewer, and CiteSpace to systematically evaluate the research landscape and emerging trends.
A total of 1,210 publications on scRNA-seq in kidney diseases were identified. China was the largest contributor among the participating countries, demonstrating consistent annual growth in publication numbers. The major research institutions were Harvard Medical School, Sun Yat-sen University, and Shanghai Jiao Tong University. Most articles in this field were published by . In a list of 8,984 authors, the most productive authors were B. D. Humphreys, Haojia Wu, and Matthias Kretzler. The dominant categories identified in this search were scRNA-seq, disease progression/mechanisms, and gene regulation/expression. Several budding areas of investigation were also noted, including immunotherapy and scRNA-seq innovations, which allude to active evolution in the field.
This bibliometric analysis revealed the rapid growth and evolving landscape of scRNA-seq applications in kidney disease research and highlighted promising opportunities for understanding disease mechanisms and developing personalized therapeutic strategies.
单细胞RNA测序（scRNA-seq）通过在细胞水平上实现高分辨率转录组分析，彻底改变了肾脏疾病研究。这项技术可以克服传统批量测序的局限性；揭示疾病进展轨迹、细胞间通讯网络和细胞异质性；并为疾病机制提供关键见解，从而促进靶向治疗和个性化治疗策略的发展。我们使用科学网核心合集（WoSCC）数据库对2015年至2024年描述scRNA-seq在肾脏疾病研究中的应用的出版物进行了文献计量分析。使用R包Bibliometrix、VOSviewer和CiteSpace进行数据分析，以系统地评估研究格局和新兴趋势。
共识别出1210篇关于scRNA-seq在肾脏疾病中的出版物。中国是参与国家中贡献最大的，出版物数量呈持续年度增长。主要研究机构是哈佛医学院、中山大学和上海交通大学。该领域大多数文章由……发表。在8984名作者的名单中，发文量最多的作者是B. D. Humphreys、吴浩嘉和马蒂亚斯·克雷茨勒。本次检索中确定的主要类别是scRNA-seq、疾病进展/机制和基因调控/表达。还注意到了几个新兴的研究领域，包括免疫疗法和scRNA-seq创新，这暗示了该领域的积极发展。
这项文献计量分析揭示了scRNA-seq在肾脏疾病研究中的应用迅速增长且不断演变的格局，并突出了理解疾病机制和制定个性化治疗策略的广阔机遇。
